Science Advance: Hepatitis C Therapeutic Registry & Research Network (HCV-TARGET)

May is hepatitis awareness month. Emory’s James Spivey, MD is an ACTSI investigator and an HCV-Target investigator. The Hepatitis C Therapeutic Registry and Research Network, or HCV-TARGET, is an international research consortium created to inform the ongoing transformation of hepatitis C treatment and research. Led jointly by the University of Florida and the University of North Carolina at Chapel Hill, HCV-TARGET follows how newly approved therapies for hepatitis C are used and managed in routine practice. It includes 103 academic and community sites in 31 states, Puerto Rico, Canada and Europe as well as collaborations with multiple industry sponsors, regulatory agencies and the patient advocacy community. As more patients get tested for hepatitis C and as new treatments enter the market, HCV-TARGET aims to provide timely data that can inform and improve the hepatitis C patient experience.

HCV-TARGET is rooted in the infrastructure and collaborative network of the CTSA consortium. While neither CTSA nor NIH grant dollars directly fund HCV-TARGET, the network uses REDCap and the UF CTSI Biorepository, and more than 25 CTSA-supported institutions (including Emory) are among HCV-TARGET’s academic and community sites.